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aides je ne peux pas accomplir mon travail dans le laboratoire.  
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If you ask me what’s the common point between classical music and chemistry in 
polyketide-synthase. It’s difficult for me to give a correct answer. They are totally 
different! I frequently complained to my “mother” and “father” about how different is this 
world with that world. They just kept appeasing me, telling me the story about Russian 
composer Borodin, who was both chemistry master and classical music master.  
When I was 4, I tried to watch television about advanced calculus that shocked my 
parents. They decided to let me do something more “normal”. Thus, I was met with my 
piano teacher and his wife, my actual “father” and “mother”. Since then, I was immerged 
with classical music for over 20 years. I spent most time of my childhood with classical 
music. Beethoven, Wagner, Mozart, Palestrina, Victoria, Puccini, Bizet, Couperin, 
Rameau… all are my favorites. My piano teacher is a conductor and a pianist, a talented 
musician. His wife is an opera singer, who can fluently speak 7 languages, also a talented 
musician. They both travelled a lot especially to Europe. I still remember the time when 
they showed me the beautiful landscape of each European countries. I love the blue of 
Mediterranean; I miss the white of Alps; I remember the green of Schwarzwald. As the 
other students they have, studying music, going to musical school, going to Europe and 
becoming a musician seemed like the right track for me. I did play piano very hard and, as 
I thought, very well when I was a kid. When most of other kids were playing, I could play 
Chopin’s études and polonaises without any difficulties. I was dreaming having concerts 
in Europe as a successful pianist and teaching piano in musical school. I watched opera 
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quiet often as well. Wagner was, and for sure always is, my most favorite composer. My 
favorite Wagnerian piece is not Der Ring des Nibelungen but Parsifal.  
However, when it was the time to decide whether to go to special conservatory 
preparative school (usually 13), I was seriously frustrated by my music teacher that I could 
not have the chance because they said I was too lazy and stupid. That heartrending moment 
when I had the conversation with them truly left me mourning and weeping in this valley 
of tears. They said, you couldn’t do whatever you wanted to do. Musicians need 
serendipity. Otherwise you could only have a miserable life. Why not find other hobbies 
as your future?  
Well, I had to face the reality. Except music, chemistry is another hobby for me. 
Then I started my chemistry journey! I was matriculated into my undergraduate college as 
a chemistry major without even taking entrance exam due to excellent score in high school 
chemistry competition.  During my undergraduate studies, I chose organic chemistry as my 
research direction. Organic chemistry is an interesting subject. I loved those name reactions 
and mechanism as well. Most of these name reactions were memorized by their inventors, 
usually American, German and Japanese. During this time, I gradually developed the idea 
going to a foreign country to continue my PhD study. US, Germany and Japan are all ideal 
options for me. I hesitated to make the decision and finally was convinced going to US.  
Everything is so coincident. The University of Texas gave me the first offer and 
then I showed up in Austin. And then I anchored finally in Dr. Adrian Keatinge-Clay’s lab 
playing with polyketide-synthase. I still remember the first day walking into his office 
discussing polyketide with him. I must say Dr. Keatinge-Clay was indeed among the 
smartest person I have ever met in science field. He is not only smart but also tall and 
handsome. According to my arrogant opinion, it is a pity Dr. Keatinge-Clay didn’t become 
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a movie star! Anyway, he outsmarted me almost in every aspect. Only in graduate school, 
I realized how hard was the PhD chemistry study: Just the same as in the music school. No 
weekends, few parties, little leisure time, and more smart and diligent persons! I was 
suffered with huge mental pressure. However, Dr. Keatinge-Clay is very nice. He allowed 
me to “vent” myself when I didn’t feel comfortable working in the laboratory. I used 
vacations taking journeys in Europe. I visited 10 countries totally, all by wheels. For sure, 
mental ventilation was very important: it significantly raised the working efficiency and 
reduced the mental pressure!  
Beyond Dr. Keatinge-Clay’s academic guidance, labmates coordination is also 
important. In my PhD study, there were plenty of people gave me generous aids. Dr. Bailey, 
Dr. Cole, Dr. Zeng, Dr. Meinke, Dr. Wagner and Mr. Valencia gave me various academic 
guidance in my PhD study and allowed me to participate in their research. Ms. Luna, Ms. 
Hirsch, Mr. Cepeda, Mr. Kumru contributed a large part to my research and finish plenty 
of works for me. Without you all I couldn’t finish work by myself. 
At the end of this chapter, I am going to answer that question in the beginning. 
Classical music and chemistry in polyketide-synthase do have same points! First, they are 
all difficult and require hard work. Second, some people study them. Third, these people 
are more intelligent and more diligent than me. Fourth, these people are great person. 
Finally, these people truly enjoy it and dedicate their lives to it. Although I cannot become 
another Borodin, thank you Dr. Keatinge-Clay, for your mentorship in my graduate school. 
Thank you also all my defense committee members, Dr. Anslyn, Dr. Iverson, Dr. Liu and 
Dr. Que, for guidance with my PhD study. Sometimes I still feel very strange how could I 
finish my PhD study in Chemistry. With joys and tears, I cannot believe most of my work 
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Nowadays the development of new-generation drugs has been rendered with high 
urgency in pharmaceutical industry, since existing medicines are not adequate to cope with 
new appeared diseases. Among these medicines, anticancer and antibiotic are the most 
important two categories which require new drugs to meet the need of frustrated patients. 
More efficacy and less toxicity are the target of developing new-generation drugs in the 
future. However, the intrinsic complexity of these chemicals compromises the effort for 
organic chemists to synthesize them in an eco-friendly and efficient way. In traditional 
organic chemistry, complex compound always means long synthetic routine, bad total yield 
and usually expensive and toxic chiral catalyst.    
Au contraire, biology now gives organic chemists an alternative way to mull the 
synthetic routine in a different view. In the natural world, plenty of useful complex 
potentially medicinal molecules are synthesized in an efficient and eco-friendly way with 
delicate stereochemistry. Room temperature, atmospheric pressure, aqueous environment, 
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neutral pH and recyclable catalyst all lure chemists into the world of enzymatic 
biocatalysis.  
We study polyketide synthases to learn the mechanism how they function to 
produce polyketides. In our laboratory, we not only utilize enzyme to synthesize complex 
chiral compound but also explore the intrinsic structure of these enzymes.  
We first introduce the new developed general chemo-enzymatic polyketide 
synthesis using ketoreductases. We successfully synthesized a library of four complex 
polyketides with two chiral centers involving two ketoreductases. In order to prove our 
result, we found a strategy to chemically synthesize the same molecule as well involving 
high pressure catalytic hydrogenation. We also report a seven-enzyme cascade reaction to 
synthesize another complex polyketide derivative in one-pot with a technique to monitor 
the reaction in situ. We studied the mechanism of pyran synthase in a trans-acyltransferase 
assembly line. By mutagenesis we determined the catalytic domain of the pyran synthase 
using chemically prepared analogues. We also studied the mechanism of monomethylation 
and dimethylation in a methyltransferase module. Finally, we conducted docking motif 
swapping proving the portability of docking domain in trans-Acyltransferase PKS 
modules.  
With the development of our study, we not only hope to explore more structural 
and functional details about the PKSs but also strive to use our enzyme to create more 
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Chapter 1:  Introduction 
A BRIEF VIEW OF POLYKETIDES IN PHARMACEUTICAL INDUSTRY 
To general consumers, products labeled with ‘natural’ and ‘organic’ are considered 
as good and healthy, but ‘chemicals’ have negative connotations as ‘unnatural’. The 
simplest definition of a natural product is a small molecule that is produced from a 
biological source. Thus, natural products and natural product mimics have become a hot 
topic followed by researchers in both chemistry and biology fields.1 In pharmacy industry, 
researchers use natural products as lead structures to discover and develop the final drug 
entity. Indeed, besides synthetic drugs, natural products and their analogs (including 
unaltered natural product, botanical drug, natural product derivative and mimic of natural 
product) are important sources of new approved drugs. For example, from circa the 1940s 
to the end of 2014, among the 175 small molecules approved by FDA in the area of cancer, 
49% are either natural products or their derivatives.2 However, compared to synthetic 
drugs, natural products still have many disadvantages, such as controversy on intellectual 
property rights, slow working progress, complexity of chemistry and, most importantly, 
difficulties in access and supply. Until recently, many large pharmaceutical companies had 
reduced the proportion of natural products in drug discovery, but now there has been a re-
emergence of natural products, evenly distributed as small-molecule drug candidates, in 
the develop pipelines.3 
A preeminent prototype of the natural product limitations describe above is the 
series of halichondrins, antitumor polyethers first separated from the marine sponge 
Halichondria okadai in 1986 (Figure. 1.1). There were eight total anti B-16 melanoma cells 
halichondrins isolated, but the major product extract, norhalichondrin A (Figure. 1.1), gave 
only 5×10-6% yield.4 Among these extraordinarily sophisticated compounds, halichondrin 
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B (Figure. 1.1) demonstrates exceptional biological inhibition against cancer (IC50=0.3 nM 
for L1210 murine leukemia cells).5 Albeit halichondrin B has such a strong potency against 
cancer, access and supply difficulties severely restricted future efforts for development. 
Thus, based on the structure of halichondrin B, its simplified analog ER-086526 (known 
as Eribulin) (Figure. 1.1), which retains the activity of halichondrin B in vitro and in vivo, 
has been developed synthetically to treat breast cancer, colon cancer, melanoma, and 
ovarian cancer.6 Later the FDA approved Eribulin in treating late-stage breast cancer.7 
 
Figure 1.1. Sea Sponge Halichondria Okadai, Eribulin, Norhalichondrin A and 
Halichondrin B.9    
Halichondrins belong to the polyketide family. Polyketide derivatives, among the 
most important microbial metabolites for human medicine, comprise a remarkable 
percentage (20% of the top-selling drugs) of pharmaceutically relevant natural products. In 
pharmacy, polyketides are utilized as antibiotics (erythromycin A, rifamycin S), anticancer 
drugs (doxorubicin, epothilone), cholesterol-lowering agents (lovastatin), antiparasitics 
(avermectin), antifungals (amphotericin B), insecticides (spinosyn A) and 
immunosuppressants (rapamycin).10 The hit rate of polyketide metabolites to be chosen as 
commercial pharmaceuticals is 0.3%, much better than the hit rate of synthetic compound 
libraries using high-throughput screening (HTS), which is <0.001%.11 
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Due to low abundance of natural products when sourced from their native 
environment, total synthesis becomes an alternative. Despite the complicity of some 
polyketides, the total synthesis of polyketides appeals to many synthetic chemists. 
Erythromycin A (Figure 1.2), generated by a strain of Streptomyces erythreus, is the best 
known of the macrolide antibiotics, a subcategory of polyketide antibiotics.  
 
Figure 1.2. The Structure of Erythromycin A.12 
Erythromycin A contains a 14-membered lactone ring with 10 asymmetric centers, 
and L-cladinose and D-desosamine residues.12 Thus, this complex compound, citing the 
greatest synthetic chemist Woodward’s word, “looks at the present time quite hopelessly 
complex, particularly in view of its plethora of asymmetric centers.”13 Woodward himself 
did not witness the completion of the total synthesis of erythromycin A. His student, Kishi, 
finally completed this project in 1981.12 Kish also incredibly finished the total syntheses of 
other members in the halichondrins family, including halichondrin A/B/C and 
norhalichondrin B.14  
USING POLYKETIDE SYNTHASES TO BUILD CHIRAL BUILDING BLOCKS 
Although asymmetric methodologies have progressed significantly in past decades, 
the total syntheses of polyketides still remain difficult due to high step counts, low atom 
economy, and involution of expensive/toxic metal catalysts preventing wide application of 
chemical synthetic polyketides. One eclectic way to promote the efficacy of synthesis is 
using a chiron approach strategy. A “chiron” (chiral synthon) is interpreted as an 
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enantiopure “synthon”.15 In the chiron approach, the target molecule is synthesized from 
enantiomerically pure chiral building blocks “chirons”, usually prepared biocatalytically 
from natural sources, such as enzymes.16 Currently there are many mature affordable 
biocatalytic chiral building blocks involved in pharmaceutical industry synthesis.17 This 
semi-synthesis strategy is powerful and amenable to the preparation of structurally similar 
complex analogs, which can be assembled quickly from the simple building blocks with 
subsequent chemical processing.18 Therefore, it is exciting for us developing an enzymatic 
system, using polyketide synthases (PKSs), to generate polyketide building blocks.  
Polyketide synthases (PKSs) are a family of complex enzyme systems responsible 
for stepwise biosynthesis of natural polyketides. Using simple CoA-activated extender 
units like acetyl/propionyl/butyryl-CoA, and malonyl/methylmalonyl/ethylmalonyl-CoA, 
their activated derivatives, polyketide synthases can elongate the main chain to finally 
reach complex final products. From an activated acyl starter unit, polyketides are elongated 
by repetitive decarboxylative Claisen thioester condensations with different extender units 










Figure 1.3. 3.2Å-resolution Structure of type I PKS of the Porcine FAS and the General 
Mechanism of Chain Elongation Catalyzed by KS.20 
A chain elongation involves a ketosynthase (KS) catalyzing the decarboxylative 
Claisen condensation, an acyl transferase (MAT/AT) selecting the extender unit, and a 
phosphopantetheinylated acyl carrier protein (ACP) tethering the growing polyketide chain 
to the next domain. After every elongation, the β-oxo functionality may be processed by a 
ketoreductase (KR) stereoselectively reducing the β-carbonyl group to a hydroxyl group 
by a dehydratase (DH) dehydrating β-hydroxyl group to olefin,  and then an enoyl reductase 
(ER) reducing olefin to alkane. Finally thioesterases (TE) catalyze hydrolysis and 
macrocyclization of polykeyide chain from the previous ACP domain to release the 
product. A set of KS, AT, and ACP domains, alongside other optional processing domains 
together compose a module, which is responsible for a single elongation cycle (Fig. 1.4). 
For Modular PKS of Type I PKS, the number of modules is related to the number of 
elongation cycles executed by the PKS.21 In the case of pikromycin, six modules of the 
pikromycin PKS sequentially extend and modify the polyketide intermediate for every 
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round of extension, and the TE finally hydrolyzed the polyketide intermediate, leading to 
either 10-dml from module 5 or narbonolide from module 6.22 
 
 
Figure 1.4. Modular Polyketide Synthase for Polyketide Narbonolide. An intermediate of 
pikromycin.22 
Modular PKSs are predominantly found in actinobacteria, myxobacteria, 
pseudomonades, and cyanobacteria. A minimal module from Modular PKS is comprised 
of a KS domain, an AT domain, and an ACP domain with optional KR domain, DH 
domain, and ER domain (Fig. 1.5).23 
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Figure 1.5. The Structure of Two Modules from a Multimodular PKS including Dimeric 
KS, AT, DH, KR, ACP and ER.24 
PAST WORK IN OUR LAB 
Using PKSs, we have a mature technique to synthesize a library of diketide chiral 
building blocks. A scalable chemo-enzymatic reaction generating chiral diketides from α-
substituted, β-ketoacyl N-acetylcysteamine thioesters has been well developed using 
isolated modular polyketide synthase (PKS) ketoreductases (KRs). The reaction is a 
biocatalytic reduction powered by regenerable glucose-fueled NADPH cycle.25 Based on 
our previous work with diketides, we have also developed a methodology to generate 
triketide pyrones26 and a versatile in vitro PKS platform to access six triketide lactones 
produced at larger scales. The terminal module and TE of the erythromycin PKS 
(EryMod6TE), a module that accepts non-natural substrates, is the core of this biocatalytic 
platform.27 The extender units with truncated substrate mimics applied in the reaction can 





Chapter 2:  General Chemo-enzymatic Synthesis Involving 
Ketoreductase to Triketide Building Blocks 
INTRODUCTION 
In previous study, we discovered that the KR determines both the stereoselectivity of the 
hydroxyl group and the neighboring α-methyl group, producing two consecutive 
stereogenic centers, in one biocatalytic KR reduction.29 In modular polyketide synthases, 
only a few certain residues control the stereospecificity of the product, and so the 
stereoselectivities can be deduced from conserved residues. Those KRs can also be 
categorized by the stereocenter created. A-type KRs generate L-β-hydroxyls and B-type 
KRs generates D-β-hydroxyls.30 Later, this nomenclature system was polished by imposing 
extra denominations onto the α-methyl substituted diketides: D-α-methyl groups are 
counted as “1,” and L-α-methyl groups are counted as “2”. Therefore, a diketide-SNAC 
would produce the “2R, 3S” product if reduced by an A1-type KR, the “2S, 3S” product if 
reduced by an A2-type KR, the “2R, 3R” product if reduced by a B1-type KR, and the “2S, 
3R” product if reduced by a B2-type KR. However, if a KR cannot reduce the carbonyl 
group, it is named a C-type KR (Figure. 2.1). We also found β-keto-SNACs were suitable 
enough to retain their natural stereoselectivites in the KR domain as the NAC handle 
mimics the acylated phosphopantetheinyl arm of the ACP domain.29 
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Figure 2.1. Chemo-enzymatic Synthesis to Chiral Building Blocks by KRs from DEBS 
PKS.25 
(A) 6-Deoxyerythronolide B synthase (DEBS) assembly line to 6-dEB. 
(B) The reduction of diketide-SNACs, with the help of GDH regenerating NADPH through 
the oxidation of D-glucose. 
(C) A general synthesis to α-substituted, β-keto diketides. 
(D) Nomenclature system of the library of diketide chiral building blocks. 
Since a library of diketide building blocks was already established. It was logical to extend 
the diketide into more complex triketide. However, during the extension of diketides by 
EryMod6TE, we found a serious side-reaction, thioesterase (TE)-mediated hydrolysis 
decomposing the thioester substrate. A triketide without protecting group anchored on PKS 
tended to self-cyclize to form more stable six-membered lactone even without the existence 
of TE. Because the cyclization prioritized the reduction, the half-life of triketide 
intermediate anchored on PKS was not long enough to allow triketide to be reduced by KR. 
In addition, due to the stereospecificity of the diketide substrate, not all chiral triketides 
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were suitable to be generated via this method, because the KS could only extend the 
recognizable subset of these chiral diketide intermediates. Thus, we had to conceived a 
new strategy to build a library of triketide building blocks without KS. The major problem 
was the extension of polyketide intermediate. We turned to biomimetic decarboxylative 
Claisen condensation,31 the key elongation step suitable for all diastereomers of diketide 
substrates. For sure there were other methods available to branched chain extension.32 
Fortunately, a chemical equivalent of KS decarboxylative Claisen condensation was 
investigated 40 years ago which could be efficient to replace the role of KS.33 Also, the 
addition of protecting group on 4-hydroxyl functionality could effectively avoid untimely 
spontaneous cyclization thus allowed triketide stay long enough on the KR to be reduced.  
Beyond KR, there was an efficient but expensive way to synthesize triketide building 
blocks by new generation metal catalyst. Asymmetric catalysis was investigated starting 
from 1960’s, when the example of experiment involving chiral transitional metal complex 
was observed. Noyori catalyst (BINAP-Ruthenium) is the most well-known metal catalyst 
in laboratory use. It is powerful to reduce various substrates including olefins and ketones 
with different functionality. The basic mechanism of such a metal complex involves three 
parts: molecular metal with chiral ligand, reactant (usually hydrogen gas) and substrate. 
The reactant and substrate first were coordinated onto the metal catalyst. The reactant and 




Figure 2.2. Basic Mechanism of Metallic Asymmetric Catalysis. A and B are reactant and 
substrate.34 
Not only Ruthenium, but also other transition metals are capable to catalyze hydrogenation 
such as Rhodium, Iridium or even Iron, due to their intrinsic similarity.35 Also in recent 
years, new generations of commercially available catalysts with improved chiral ligands 
are appearing on the market. Ir-Spiro-AP series catalyst is an example with great steric 
hindrance leading to great chiral selectivity. Characterized by new tridentate multi-chiral 
centered spiro P-N-S ligands instead of traditional P-N-P ligands (Ir-Spiro-PAP), the new-
designed Ir-Spiro-SAP perfectly performed asymmetric hydrogenation on β-ketoesters 
with high setereoselectivity, high substrate-catalyst ratio and high yield (Figure 2.3).36  
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Figure 2.3. The Preparation and Structure of Ir-Spiro-PAP and Ir-Spiro-SAP.36 
From recent research progress, Ir-Spiro-PAP was successfully applied in complex 
polyketide intermediate synthesis (-)-Cynolide A and (-)-Doliculide with good chirality 
and conversion.37 The reactions were also featured with high substrate/catalyst ratio, fast 
reaction time and excellent protection group tolerance. Thus, Ir-Spiro-PAP was conceived 
an excellent substituent of KR to reduce carbonyl in the same triketide building block 
synthesis.  
RESULTS AND DISCUSSIONS 
Chemo-enzymatic synthetic routine to Triketide Acid 
Synthesis Design 
Because the synthetic routine resembled the natural PKS enzyme, the starting material to 
begin with was propionyl-Meldrum’s acid 1, which could be easily prepared from 
commercially available Meldrum’s acid. Propionyl-Meldrum’s acid 1 could be refluxed 
with N-acetylcysteamine (NAC) in afford diketide β-keto-diketide 2. β-keto-diketide 2 
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could be easily reduced to L- or the D-β-hydroxy-diketide 325 in aqueous solution 
depending on the KR enzyme chosen. MycKR6 would lead to L-β-hydroxy-diketide 3 and 
TylKR2 would lead to L-β-hydroxy-diketide 3 respectively. The reduction system 
characterized by a regeneration system involving nicotinamide adenine dinucleotide 
phosphate (NADPH), glucose dehydrogenase (GDH) and D-glucose, which was designed 
to regenerate KR in situ. β-hydroxy-diketide 3 was subsequently hydrolyzed to give 
corresponding β-hydroxy acid 4. β-hydroxy acid 4 could be modified by protecting group 
to generate protected acid 5’ in order to exclude self-cyclization later in enzymatic 
reduction. Protected acid 5’ as polyketide chain should react with malonyl ethanethiol 
thioester as extender unit to afford β-keto-triketide 6’. Thiol-thioester exchange of β-keto-
triketide 6’ in situ with the existence of excessive NAC should give ideal compound NAC-
bound β-keto-triketide 7’. NAC-bound β-keto-triketide 7’ would afterwards be reduced to 
give β-hydroxy triketide 8’ by either MycKR6 or TylKR2 giving L/D configuration 
respectively. Subsequent hydrolysis of β-hydroxy triketide 8’ would finally give target 
compound triketide acid 9’ (Figure 2.4). 
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Figure 2.4. Proposed Synthesis Schedule for Triketide Acid 9’. 
Total Synthesis  
An improved procedure with the beginning two steps based on our previous work was 
utilized to synthesize large quantity starting material with a higher purity.25 Pyridine and 
propionyl chloride were consecutively added to Meldrum’s acid in cold DCM solution to 
give propionyl-Meldrum’s acid 1 without chromatography separation in a 70% yield.38 
Propionyl-Meldrum’s acid 1 was then refluxed at 115 °C with NAC in toluene to give β-
keto-diketide 2 with 61% yield as a dark yellow solid. Flash chromatography with copper 
sulfate impregnated silica was employed in to remove unreacted NAC during separation. 
The NAC handle was necessary for KR biocatalysis as well as other similar handle like 
ethanethiol, because they were mimics of the natural ACP side chain to afford greater 
stereocontrol39. Water soluble β-keto-diketide 2 was then incubated with either MycKR6 
to generate β-hydroxy-diketide 3a or TylKR2 to generate β-hydroxy-diketide until reaction 
was completed (usually overnight, depending on the quantity of enzyme).25 Reaction of β-
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keto-diketide 2 with the A-type KR MycKR6 provided β-hydroxy-diketide 3a in 65% 
yield, whereas reaction with the B-type KR TylKR2 provided β-hydroxy-diketide 3b in 
58% yield. These enantiomers were sticky yellow oil with a specific odor. Stereochemistry 
of these enantiomers and standards were measured and compared by chiral HPLC (Figure 
S3A-1/S3B-1). Both enantiomers were afterwards hydrolyzed overnight at 80 oC by adding 
5 M sodium hydroxide solution, giving the corresponding L-β-hydroxy acid 4a and L-β-
hydroxy acid 4b in respectively 51% and 59% yields; this hydrolysis removed the 
contaminant NAC and its oxidized dimer generated during the reaction (Figure 2.5). 
 
Figure 2.5. Synthesis from 1 to 4. 
Conditions: a) 1) pyridine (2.0 eq.), propionyl chloride (1.0 eq.), DCM, overnight, 0 to 22 
ºC (76% yield); 2) N-Acetylcysteamine (NAC, 0.95 eq.), toluene, 115 ºC, 5 h (61% yield), 
b) Either MycKR6 (A-type KR) for 3a or TylKR2 (B-type KR) for 3b, GDH, NADP+, pH 
7.7, overnight, 22 ºC (3a, 65%, 3b, 58%), c) 5 M NaOH aq., 80 ºC, overnight (4a, 51%, 
4b, 59%). 
Regarding the β-hydroxyl substituent, several protecting groups were considered, as acetyl, 
methyl, methoxymethyl, and even silyl groups. The acetyl protecting group was attempted 
first and did give desired product. However, during the second reduction of triketide, when 











































material. Therefore, methyl protecting group with high stability was chosen to protect the 
β-hydroxy acid 4b since O-methylation was common in natural polyketides biosynthesis. 
O-methyltransferase (O-MT) domains existed in PKS system which often methylated β-
hydroxyl substituents. Therefore, unlike those larger silyl groups, the methyl protecting 
group was chosen because its small steric hindrance wouldn’t prevent the target polyketide 
from the catalytic sites of downstream enzymes (KR). The β-hydroxy acids 4a and 4b 
reacted with n-butyllithium in DMSO first and then were methylated by methyl iodide, 
giving respectively L/D-β-methoxy acids 5a and 5b in 73% and 78% yields as a dark 
yellow oil. The reaction could be easily monitored by color change since the dianion (dark 
brown) and monoanion (light orange) had different colors. When methyl iodide was added 
into the system, the color shifted from dark brown gradually to light orange. According to 
the original report, this reaction was intended for synthesizing dimethylated acids 10a and 
10b. However, based on observation actually it only generated the intermediate mono-
methylated compound β-hydroxy acids 4a and 4b,40 which, fortunately, were the desired 
compounds. The removal of DMSO was not necessary but could be achieved by column 
chromatography. Protected β-methoxy acids 5a and 5b reacted with malonyl ethanethiol 
thioester in mono-magnesium salt form to give important intermediate β-keto-triketide 6a 
and 6b in 35% and 34% yields, respectively.33 The product β-keto-triketide 6a and 6b were 
light fluent yellow liquid with distinct onion-like aroma. This decarboxylative Claisen 





Figure 2.6. Synthesis from 4 to 6 and the Structure of 10. 
Conditions: d) 2.5 M n-BuLi (3.0 eq.), DMSO, MeI (2.4 eq.), under argon, 22 ºC, overnight 
(5a, 73%, 5b, 78%), e) 1,1'-Carbonyldiimidazole (CDI) (1.1 eq.), Mg(OEt)2 (0.55 eq.), 
malonic acid half ethyl thioester (1.1 eq.), anhydrous THF, 22 ºC, overnight (6a, 35%, 6b, 
34%). 
As convenient thiol-thioester exchange, β-keto-triketide 6a and 6b were converted to 
NAC-bound β-keto-triketide 7a and 7b using 10 equivalents of NAC at room temperature 
in situ. The reaction could easily be monitored by TLC as well as the smell of volatile 
ethanethiol as a reaction byproduct. After installation of NAC, the pH was then turned to 
7.7 and either MycKR6 or TylKR2 alongside the NADPH regeneration system were added 
to form reduced β-hydroxy triketide 8 with a new L-/D-orientated stereocenter. However, 
due to byproducts like NAC dimer, the purifications of 8aa, 8ba, 8ab, and 8bb were too 
difficult through flash chromatography. Different conditions were attempted but only lead 
to failure. This was because β-hydroxy triketide 8 and NAC dimer had similar polarities 
on the column. Fortunately, if β-hydroxy triketide 8 was hydrolyzed using aqueous 5 M 
sodium hydroxide at 70 °C, the purification of corresponding triketide acid 9 was relatively 
simplified. Hydrolysis could remove majority of the byproducts, including NAC dimer, 
from the reaction mixture, to generate final compound triketide acids 9aa, 9ba, 9ab, and 








































Figure 2.7. Synthesis from 6 to 9. 
Conditions: f-h) NAC, pH 8.5, 22 ºC, 2 h, then either MycKR6 (A-type KR) or TylKR2 
(B-type KR), GDH, NADP+, pH 7.7, overnight, then 5 M NaOH, 70 ºC, overnight (yields: 
9aa, 57%; 9ab, 36%; 9ba, 44%; 9bb, 24%). 
Chemical Synthetic Routine to Triketide Acid Using Metal Catalyst 
Synthesis Design 
The synthesis of triketide acid 9’ using metal catalyst was similar to chemo-enzymatic 
synthesis. Instead of KR, Ir-spiro-SAP was utilized to reduce the carbonyl in both diketide 


















































































commercially available in bulk and also could be directly to use for reduction. Ester 12 was 
reduced to afford ester 13 by asymmetric catalysis via Ir-spiro-SAP. After that, ester 13 
was hydrolyzed to form same hydroxyl acid 3. From hydroxyl acid 3 to β-keto-triketide 6’, 
the same synthetic routine was adopted. Instead of thiol-thiolester exchange, alcoholysis 
was applied to β-keto-triketide 6’ to generate oxoester 14. Oxoester 14 was reduced by Ir-
spiro-SAP and then hydrolyzed to produce target compound triketide acid 9’ (Figure 2.8). 
 
 
Figure 2.8. Proposed Synthesis Schedule for Triketide Acid 9’. 
Total Synthesis  
Using above-mentioned Ir-spiro-SAP,37 ester 12 was readily reduced under 100 atm 
hydrogen gas in methanol almost quantitatively to form diektide 13a or 13b as a light 
yellow liquid without separation. The chirality of reduction depended on the catalyst. (S)-
Ir-spiro-SAP produced L-enantiomer whereas (R)-Ir-spiro-SAP produced D-enantiomer. 
13a and 13b were hydrolyzed using 5 M sodium hydroxide solution overnight at 80 oC, to 
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form corresponding hydroxy acid 4a and 4b in 51% and 59% yields. Afterwards the 
synthesis was the same until β-keto-triketide 6a and 6b. During alcoholysis, excessive 
sodium methoxide in methanol was employed to transform β-keto-triketide 6a and 6b into 
oxoester 14a and 14b with moderate yields 27% and 16% as slightly aromatic yellow oil. 
Luckily most unreacted β-keto-triketide 6a and 6b could be recycled by chromatography 
whereas part of them was lost due to side-reaction. Oxoester 14a and 14b were then 
reduced by Ir-spiro-SAP again. Subsequent hydrolysis generated final compound triketide 
acid 9aa, 9ab, 9ba and 9bb as yellow oil respectively through two steps (77%, 97%, 83%, 
86%). This synthetic routine allowed a larger quantity than chemo-enzymatic synthesis 




Figure 2.7. Synthesis from 12 to 9. 
Conditions: a) Either (S)-Ir-spiroSAP, 100 atm H2, MeOH, 22 ºC, 48 h for 11a or (R)-Ir-
spiro-SAP, 100 atm H2, MeOH, 22 ºC, 48 h for 11b (both yields >99%), b) 5 M NaOH aq., 
80 ºC, overnight (4a, 51% and 4b, 59%), c) 2.5 M n-BuLi (3.0 eq.), DMSO, MeI (2.4 eq.), 
under argon, 22 ºC, overnight (5a, 73% and 5b, 78%), d) 1,1'-Carbonyldiimidazole (1.1 
eq.), Mg(OEt)2 (0.55 eq.), malonyl ethanethiol thioester (1.1 eq.), anhydrous THF, 22 ºC, 
overnight (6a, 35% and 6b, 34%), e) sodium methoxide (10.0 eq), anhydrous MeOH, 22 
ºC, 6-9 h, (12a, 27% and 12b, 16%), f) Either (S)-Ir-spiroSAP, 100 atm H2, MeOH, 22 ºC, 
48 h then 5 M NaOH aq., 60 ºC, overnight for 9aa and 9ba or (R)-Ir-spiroSAP, 100 atm 
H2, MeOH, 22 ºC, 48 h then 5 M NaOH aq., 60 ºC, overnight for 9ab and 9bb (9aa, 77%; 











































































Although 1H NMR did demonstrate difference between syn-isomer 9aa and 9bb from their 
anti-isomer 9ab and 9ba. Slight chemical shift difference on the hydroxyl proton was 
observed around 4.2-4.3 ppm. However, there were often impurities generated in 
enzymatic reduction, which appeared around this area, causing difficulty to interpret the 
result. Therefore, 13C NMR technology was preferred over 1H NMR to interpret the 
stereochemistry because it was straightforward and facile to exclude impurity interference. 
The interpretation of 13C NMR was based on Hoffmann’s empirical rule.41 The signals of 
C-3, C-5 of anti-isomers 9ab and 9ba were at higher field than their syn-isomers 
counterparts because due to intramolecular hydrogen bond anti-isomers adopted chair 
conformations (for sure the terms threo- and erythro- are better). Therefore, there were 
more stereo-hindrance in anti-isomers 9ab and 9ba because the substituents were likely to 
be axial instead of equatorial (Figure 2.10). 
 
 
Figure 2.10. 13C NMR Comparison of C-3, C-5 in syn-isomers and anti-isomers of 9. The 
triketide stereoisomers stereochemistry could be assigned using Hoffmann’s rule by adding 
the 13C NMR shifts of the C3 and C5 signals together: the anti-isomers (e.g., 9ba) would 
give a smaller d(C3)+d(C5) value than syn-isomers (e.g., 9aa) because of axial substituents 
on the chair conformation.  
Regarding 9aa and 9ba, the conformation seemed to adopt C-3 as axial substituent since 
in 9ba there was more difference observed in chemical shift of C-3 than that of C-5. In 13C 
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NMR, the chemical shift difference was obvious (~3 ppm for C-3, ~2 ppm for C-5) so that 
there was no chance to confuse syn-isomer with anti-isomer. Also, there were difference 
of other carbon atoms (C-1, C-2 and C-7) in chemical shift, which excluded interference 
of impurities and demonstrated high credibility using 13C NMR to determine the 
stereochemistry (Figure 2.11). On both 1H NMR and 13C NMR, all stereoisomers from 




Figure 2.11. 13C NMR Comparison of Major Peaks in syn-/anti-isomers of 9. Syn-isomers 
have the same chemical shift pattern different from anti-isomers. 
Chromatography 
Two complementary, chiral chromatography systems were used to determine which 
stereoisomers were generated in the chemo-enzymatic synthesis of triketides 8aa, 8ab, 
8ba, and 8bb - an OC-H column (normal phase) coupled with a UV detector and an IF3 
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column (reversed phase) coupled with a time-of-flight (TOF) mass spectrometer (Figure 
5). The peaks of anti-products, 8ab & 8ba, were always observed before those of the syn-
products, 8aa & 8bb, in both chromatography. Albeit the anti-products could not be 
separated from each other on the OC-H column, they could be separated on the IF3 column 
fortunately. Similarly, the syn-products could not be separated from each another on the 
IF3 column, but they could be separated on the OC-H column. In all of the cases, the 
targeted stereoisomer was the majority (at least 90%) of all stereoisomers. Therefore, it 
was concluded the A-type KR MycKR6 and the B-type KR TylKR2, which were robust 
towards diketide NAC thioesters9 stereoselectively, were robust also towards triketide 





Figure 2.12. Chiral Chromatography of Chemo-enzymatically Generated 8aa, 8ab, 8ba, 
and 8bb. by two systems: an OC-H column with a UV detector (left) and an IF3 column 
with a time-of-flight mass spectrometer (right). The OC-H column was capable to resolve 
the syn-products, whereas the IF3 column was capable to resolve the anti-products. 
Retention times matched those of standards (Table S1). For each target species, the desired 
triketide stereoisomer comprises at least 90% of all four possible stereoisomer products. 
Chemical Standard Comparison 
In order to compare products from both synthetic routine, chemically synthesized 9 was 
transformed to 8 inspired by previous work (Figure 2.13).42 Surprisingly but expected, the 
products from metallic reductions showed exactly the same stereoselectivity as predicted 
from reactions with β-ketoesters, with (S)-Ir-spiro-SAP yielding an (S)-β-hydroxyl group 
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and (R)-Ir-spiro-SAP yielding an (R)-β-hydroxyl group. In a word, the chemically 
synthesized 8aa, 8ab, 8ba, and 8bb had the same characteristics on HPLC and LC/MS 
with enzymatically synthesized 8aa, 8ab, 8ba, and 8bb. Thus based on the analysis that 
the research results were trustworthy. 
 
 
Figure 2.13. Synthesis from 9 to 8. 































































Equipment and Settings for Characterization 
NMR: NMR 400 MHz Agilent and NMR VNMRS 600 MHz Agilent  
HPLC condition (normal-phase, chiral): Daicel Chiralcel OC-H dp 5 µm 4.6 mmx25 cm, 
Beckman Coulter HPLC system with a 20 µl loop, UV 230 nm.  
Condition: 7% ethanol 93 % hexane 0.8 ml/min. 
LC/MS analysis (for all pure compounds) 
Agilent Technologies 6530 Accurate-Mass Q-TOF, Direct Inject, Jet Stream Ion Source 
ESI, in positive/negative mode. 
LC/MS analysis (reverse-phase, chiral, for triketide reaction reactant) 
Agilent 1260 Infinity II HPLC with an Agilent 6230 TOF ESI instrument, in positive mode; 
CHIRALPAK®IF-3 column, 4.6 mm × 250 mm, 3µm; column temperature of 30°C.  














Protein preparation  
The expression plasmids for MycKR6, TylKR2, and GDH as well as the purification of 
GDH have been previously described25. To harvest large quantities of KRs for the 
biocatalytic reactions, ammonium sulfate precipitations were performed. After growing 6 
L of transformed E. coli BL21(DE3) in LB supplemented with 50 mg/L kanamycin to 
OD600=0.6, cells were harvested through centrifugation (4000 x g, 10 min). They were then 
resuspended in 75 mL lysis buffer [30 mM HEPES, 500 mM NaCl, 5% (v/v) glycerol, pH 
7.0], sonicated, and centrifuged (30,000 x g, 30 min) to obtain the cell lysate. Ammonium 
sulfate was slowly added to the lysate while stirring at 4 °C until the solution was 65% 
saturated. The mixture was centrifuged (30,000 x g for 30 min) to yield protein pellets that 
were stored at -80 °C. 
Precipitate is from lysate (Figure 2.14). 
 
Figure 2.14. Protein Gels for MycKR6, TylKR2, and GDH. 
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Synthesis and Characterization 
Synthesis of 2 
 
Meldrum’s acid (7.2 g, 50.0 mmol) was dissolved in 80 mL dry DCM at 0 °C, and pyridine 
(8 mL, 100 mmol) was added to the solution. Propionyl chloride (4.35 mL, 50 mmol) was 
then supplied dropwise over 15 min. The color of the system gradually turned dark orange. 
The reaction was allowed to warm to 22 °C (r.t.) and stirred overnight. After that, the 
reaction was washed with 6 x 50 mL 0.1 M HCl to remove pyridine. The organic layer was 
dried over Na2SO4 and concentrated under reduced pressure. Crude 1 (7.6 g, 76.0%) was 
obtained as dark orange crystals and used directly in the next step. 
 
1 (16.8 g, 200 mmol) was dissolved in 150 mL dry toluene, and N-acetylcysteamine (NAC, 
9.5 g, 119 mmol) was added. The reaction was refluxed at 115 °C for 5 h. The reaction was 
then cooled down to 22 °C, and the solvent was removed through reduced pressure. 
Purification of the residue through CuSO4-impregnated silica gel gave 2 (11.1 g, 61%) as 
a light yellow to dark brown solid. Column conditions used for half of the crude product: 
6 x 11 cm; 600 mL (2:1 hexane: EtOAc), 600 mL (1:1 hexane: EtOAc), followed by pure 
EtOAc until all of the product was eluted. 
 
1H NMR (400 MHz, chloroform-d) δ 5.97 (s, 1H), 3.69 (s, 2H), 3.45 (m, 2H), 3.08 (t, J = 
6.0 Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 1.96 (s, 3H), 1.10 (t, J = 7.2 Hz, 3H). 
13C NMR of 2 (101 MHz, chloroform-d) δ 202.61, 192.40, 170.45, 56.91, 39.17, 36.73, 
29.20, 23.19, 7.48. 
HRESIMS of 2 m/z 218.0850 [M+H]+ (218.085091 calculated for C9H16NO3S). 
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Syntheses of 3a and 3b 
 
Syntheses of 3a 
2 (4.0 g, 18.4 mmol) was combined with 120 mL water, 144 mL 1 M HEPES (pH 7.7), 
9.6 mL 5 M NaCl solution, 80 mL 2 M d-glucose, 320 µL 150 mM NADP+, 240 µL 20 
mg/mL GDH, and 80 mL MycKR6 lysate (around 3 mg/ml). The reaction was stirred at 
22 °C overnight or until judged complete by LC/MS. To prevent emulsification, heat was 
applied, and denatured enzyme was separated by centrifugation. After that, the reaction 
was extracted with 2 L EtOAc, which was dried over Na2SO4. Solvent was removed by 
reduced pressure to give crude 3a (2.6 g, 65%) as an odorless, yellow oil without further 
separation.  
 
1H NMR (400 MHz, chloroform-d) δ 6.49 (s, 1H), 3.95 (m, 1H), 3.41 – 3.30 (m, 2H), 
3.05 – 2.93 (m, 2H), 2.75 – 2.54 (m, 2H), 1.92 (s, 3H), 1.52 – 1.42 (m, 2H), 0.90 (t, J = 
7.4 Hz, 3H). 
13C NMR (101 MHz, chloroform-d) δ 199.12, 170.76, 69.92, 50.66, 39.04, 29.59, 28.62, 
22.98, 9.69. 







Syntheses of 3b 
2 (4.0 g, 18.4 mmol) was combined with 120 mL water, 144 mL 1M HEPES (pH 7.7), 
9.6 mL 5 M NaCl solution, 80 mL 2 M d-glucose, 320 µL 150 mM NADP+, 240 µL 20 
mg/ml GDH, and 80 mL TylKR2 lysate (around 3 mg/ml). The reaction was stirred at 22 
°C overnight or until judged complete by LC/MS. To prevent emulsification, heat was 
applied, and denatured enzyme was separated by centrifugation. After that, the reaction 
was extracted with 2 L EtOAc, which was dried over Na2SO4. Solvent was removed by 
reduced pressure to give crude 3b (2.3 g, 58%) as an odorless, yellow oil without further 
separation. 
 
1H NMR of 3b (400 MHz, chloroform-d) δ 6.55 (s, 1H), 3.93 (m, 1H), 3.38 – 3.32 (m, 
2H), 2.97 (m, 2H), 2.68 – 2.57 (m, 2H), 1.91 (s, 3H), 1.52 – 1.42 (m, 2H), 0.94 – 0.85 (t, 
3H). 
13C NMR of 3b (101 MHz, chloroform-d) δ 199.03, 170.80, 69.90, 50.67, 39.01, 29.58, 
28.59, 22.96, 9.68. 










Syntheses of 4a and 4b 
 
Syntheses of 4a  
3a (2.5 g, 11.4 mmol) was dissolved in 60 mL 5.0 M sodium hydroxide and stirred at 80 
°C overnight. The solution was adjusted to ~pH 9 and washed with 3 x 50 mL EtOAc. 
Next, it was acidified to pH 1 with concentrated HCl and extracted with 5 x100 mL 
EtOAc. The organic phase was dried over Na2SO4, and the solvent was twice co-
evaporated with 20 mL toluene through reduced pressure to give crude 4a (630 mg, 51%) 
as a dark oil without further purification.  
 
1H NMR of (400 MHz, chloroform-d) δ 3.97 (m, 1H), 2.59 (dd, J = 16.0, 3.1 Hz, 1H),  
2.48 (dd, J = 16.3, 8.9 Hz, 1H), 1.67 – 1.45 (m, 2H), 0.97 (t, J = 7.5 Hz, 3H). 
13C NMR of 4a (101 MHz, chloroform-d) δ 177.60, 69.32, 40.62, 29.43, 9.78. 












Synthesis of 4b 
3b (2.6 g, 11.6 mmol) was dissolved in 60 mL of 5 M sodium hydroxide and stirred at 80 
°C overnight. The solution was adjusted to pH 9 and washed with 3 x 50 mL EtOAc. 
Next, it was adjusted to pH 1 with concentrated HCl and extracted with 5 x100 mL 
EtOAc. The organic phase was dried over Na2SO4, and the solvent was twice co-
evaporated with 20 mL toluene under reduced pressure to give crude 4b (820 mg, 59%) 
as a dark oil without further purification.  
1H NMR (400 MHz, chloroform-d) δ 3.97 (m, 1H), 2.58 (dd, J = 16.7, 3.1 Hz, 1H), 2.41 
(dd, J = 16.7, 8.9 Hz, 2H), 1.63 – 1.45 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H). 
13C NMR of 4b (101 MHz, chloroform-d) δ 177.60, 69.34, 40.60, 29.38, 9.76. 
















Syntheses of 5a and 5b 
 
 
This procedure is a modification of a published protocol.40  
 
Synthesis of 5a 
5.8 mL 2.5 M n-butyllithium in hexanes (14.5 mmol) was carefully dripped into 7.0 mL 
dry DMSO under argon. The reaction was stirred for 40 min to form DMSO lithium base. 
4a (567 mg, 4.80 mmol) was dissolved in 4.0 mL DMSO, and this solution was slowly 
added to the reaction and stirred for 2 h. 0.71 mL MeI (1.67 g, 11.34 mmol) was then 
added, and the reaction was stirred at 22 °C overnight. Then 15 mL water was added to 
quench the reaction, and the mixture was washed with 4 x 50 mL diethyl ether. The 
solution was adjusted to pH 1 and extracted with 6 x 50 mL diethyl ether, which was 
dried over Na2SO4. The solvent was passed through CuSO4-packed silica gel and 
removed under reduced pressure to give crude 5a (462 mg, 73%) as a dark oil without 
further purification. 
 
1H NMR (400 MHz, chloroform-d) δ 3.59 (m, 1H), 3.39 (s, 3H), 2.55 (dd, J = 15.4, 7.3 
Hz, 1H), 2.49 (dd, J = 15.4, 5.1 Hz, 1H), 1.69 – 1.53 (m, 2H), 0.93 (t, J = 7.5 Hz, 3H). 
13C NMR of 5a (101 MHz, chloroform-d) δ 174.88, 78.56, 56.64, 38.64, 26.09, 9.02. 




Synthesis of 5b 
7.8 mL 2.5 M n-butyllithium in hexanes (19.5 mmol) was carefully dripped into 10.0 mL 
dry DMSO under argon. The reaction was stirred for 40 min to form DMSO lithium base. 
4b (850 mg, 7.19 mmol) was dissolved in 6.0 mL DMSO, and this solution was slowly 
added to the reaction and stirred for 2 h. 1.1 mL MeI (1.67 g, 17.26 mmol) was then 
added, and the reaction was stirred at 22 °C overnight. After that, 20 mL water was added 
to quench the reaction. The mixture was washed with 4 x 50 mL diethyl ether, adjusted to 
pH 1, and extracted with 5 x 50 mL diethyl ether. The organic layer was dried over 
Na2SO4. The solvent was passed through CuSO4-packed silica gel and then removed by 
reduced pressure to give crude 5b (740 mg, 78%) as a dark oil without further 
purification. While not necessary, traces of DMSO can be removed from 5a and 5b 
through flash chromatography. Column conditions: 3 x 5 cm; 300 mL 10:1 hexane: 
EtOAc and then 5:1 hexane: EtOAc until all the product elutes. 
 
1H NMR of 5b (400 MHz, Chloroform-d) δ 3.59 (m, 1H), 3.38 (s, 3H), 2.54 (dd, J = 
15.4, 7.3 Hz, 1H), 2.47 (dd, J = 15.4, 5.2 Hz, 1H), 1.61 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 
13C NMR of 5b (101 MHz, chloroform-d) δ 174.54, 78.36, 56.35, 38.43, 25.87, 8.79. 









Syntheses of 6a and 6b 
 
Synthesis of 6a 
This protocol is modified from a reported procedure33. Portion A: 1,1'-
Carbonyldiimidazole (CDI) (1.16 g, 7.18 mmol) and 5a (863 mg, 6.53) were carefully 
dissolved in 30 mL anhydrous THF. The reaction was stirred for 6 h at 22 °C. Portion B: 
Mg(OEt)2 (411 mg, 3.59 mmol) and malonic acid half ethyl thioester (1.06 g, 7.17 mmol) 
were dissolved in 15 mL anhydrous THF, and the reaction was kept stirring for 3 h at 22 
°C. Portions A and B were then combined and stirred overnight at 22 °C. The reaction 
was quenched with 100 mL 0.5 M HCl and the aqueous layer was extracted with 3 x 100 
mL diethyl ether. The organic layer was washed with saturated NaHCO3 and dried over 
Na2SO4. The solvent was carefully removed through reduced pressure without heat. 
Purification of the residue by column chromatography gave 6a (633 mg, 35%) as a 
reddish liquid. Column condition: 3x12 cm. Eluant: 300 mL (50:1 hexane: EtOAc), 200 
mL (40:1 hexane: EtOAc) and then around 200 mL (20:1 hexane: EtOAc). When product 
is pure, column chromatography is not required. 
 
1H NMR (400 MHz, chloroform-d) δ 3.70 (s, 2H), 3.63 (m, 1H), 3.32 (s, 3H), 2.93 (q, J = 
7.5 Hz, 2H), 2.75 (dd, J = 16.5, 7.6 Hz, 2H), 2.58 (dd, J = 15.6, 4.6 Hz, 2H), 1.54 (m, 
2H), 1.27 (t, J = 7.5 Hz, 3H), 0.89 (t, J = 7.5 Hz, 3H). 
13C NMR of 6a (101 MHz, chloroform-d) δ 201.24, 192.06, 78.09, 58.43, 56.93, 47.15, 
26.17, 23.95, 14.45, 9.10. 
HRESIMS of 6a m/z 241.0874 [M+Na]+ (241.087437 calculated for C10H18O3SNa).  
 37 
Synthesis of 6b 
Portion A: 1,1'-Carbonyldiimidazole (CDI) (597 mg, 3.68 mmol) and 5b (442 mg, 3.34 
mmol) were carefully dissolved in anhydrous 15 mL THF. The reaction was kept stirring 
for 5 h at 22 °C. Portion B: Mg(OEt)2 (221 mg, 1.84 mmol) and malonic acid half ethyl 
thioester (545 mg, 3.68 mmol) were dissolved in 7 mL anhydrous THF, the reaction was 
kept stirring for 3 h at 22 °C. Portion A and Portion B were combined and kept stirring 
overnight at 22 °C. 
 
After that, the reaction was quenched with 50 mL 0.5 M HCl and partitioned by 50 mL 
diethyl ether. The aqueous layer was extracted by diethyl ether 50 mL twice and 25 mL 
once. The organic layer was washed with saturated NaHCO3 and dried over Na2SO4. The 
solvent was carefully removed by reduced pressure without heat. Purification of the 
residue via column chromatography gave 6b (251 mg, 34%) as a reddish liquid. Column 
condition: 1x12 cm. Eluant: 50:1 hexane: EtOAc until all coming out. When product is 
pure, column chromatography is not required.  
 
1H NMR (400 MHz, chloroform-d) δ 3.70 (s, 2H), 3.63 (m, 1H), 3.33 (s, 3H), 2.93 (q, J = 
7.5 Hz, 2H), 2.75 (dd, J = 15.5, 7.7 Hz, 1H), 2.58 (dd, J = 15.9, 4.7 Hz, 1H), 1.54 (m, 
2H), 1.27 (t, J = 7.6 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H). 
13C NMR of 6b (101 MHz, chloroform-d) δ 201.27, 192.08, 78.07, 58.44, 56.94, 47.16, 
26.16, 23.96, 14.46, 9.11. 










Two-stereocenter triketides were synthesized from 6a and 6b both through metallic 











Two complementary, chiral chromatography systems were used to determine which 
stereoisomers were generated in the chemoenzymatic syntheses of triketides 8aa, 8ab, 
8ba, and 8bb - an OC-H column (normal phase) coupled with a UV detector and an IF3 
column (reversed phase) coupled with a time-of-flight (TOF) mass spectrometer. The 
trans-products, 8ab & 8ba, eluted before the cis-products, 8aa & 8bb, in both 
chromatographies. While the trans-products could not be resolved from one another on 
the OC-H column, they could be on the IF3 column, and while the cis-products could not 
be resolved from one another on the IF3 column, they could be on the OC-H column. For 
all LC/MS-TOF studies, S-(2-acetamidoethyl) 3-oxohexanethioate, 11, was supplied as 
an internal standard (synthesized the same as 2, except with the use of butyryl chloride). 
Extracted ion chromatograms of triketide targets (pp. 25-26) and internal standard 11 (p. 
27) are presented.  














Using Lysate (30 ml lysate good for 100 mg starting material)  
Synthesis of 8aa & 9aa 
6a (110 mg, 0.389 mmol) was added to a solution containing 500 µL NAC (around 10 
eq.) 10 mL water, and 12 mL of 1 M HEPES (pH 8.5). The thiol-thioester exchange was 
performed over 2 h at 22 °C, and then the pH was adjusted to 7.7 with concentrated HCl. 
800 µL of 5 M NaCl, 6 mL of 2.0 M d-glucose, 160 µL of 0.15 M NADP+, 180 µL of 
GDH (15 mg/mL), and 30 mL of MycKR6 lysate (around 3 mg/ml). were then 
consecutively added to the reaction. The reaction was kept stirring at 22 °C overnight or 
until it was done monitored by LC/MS. Heat was applied by microwave, and the 
aggregated enzyme was separated by centrifugation. After that, the reaction was extracted 
by 450 mL EtOAc. The extract was dried over Na2SO4, and the solvent was removed by 
reduced pressure. Formation of 8aa and its stereoisomers could be analyzed by chiral 
chromatography. 10 mL of 5 M NaOH was added to the residue, and the reaction was 
heated to 80 °C overnight. After that, the reaction was cooled down and washed with 2 x 
50 mL EtOAc. The pH was then adjusted to 1, and the reaction was extracted with 3 x 50 
mL EtOAc. The extract was dried over Na2SO4. The solvent was passed through a plug 
of CuSO4-impregrated silica gel and co-evaporated with toluene under reduced pressure 









HRESIMS of 8aa m/z 300.1247 [M+Na]+ (300.124551 calculated for C12H23NO4SNa). 
Stereoisomer distribution determined through complementary chiral chromatographies 
(see p. 26): >90% 8aa 
 
1H NMR (400 MHz, chloroform-d) δ 4.24 (m, 1H), 3.44 (m, 1H), 3.34 (s, 3H), 2.52 (m, 
2H), 1.62 (m, 4H), 0.86 (t, J = 7.6 Hz, 3H). 
13C NMR of 9aa (101 MHz, chloroform-d) δ 176.01, 82.06, 67.96, 55.91, 41.56, 39.04, 
25.07, 8.44. 


















Synthesis of 8ab & 9ab 
6a (55 mg, 0.195 mmol) was added to a solution containing 250 µL NAC (around 10 
eq.), 5 mL water and 6 mL of 1 M HEPES (pH 8.5). The thiol-thioester exchange was 
performed over 2 h at 22 °C, and then the pH was adjusted to 7.7 with concentrated HCl. 
800 µL of 5 M NaCl, 6 mL of 2.0 M d-glucose, 160 µL of 0.15 M NADP+, 180 µL of 
GDH (15 mg/ml), and 30 mL of TylKR2 lysate (around 3 mg/ml). were then 
consecutively added to the reaction. The reaction was kept stirring at 22 °C for 2 d or 
until it was done monitored by LC/MS. Heat was applied by microwave, and the 
aggregated enzyme was separated by centrifugation. After that, the reaction was extracted 
by 450 mL EtOAc. The extract was dried over Na2SO4, and the solvent was removed by 
reduced pressure. Formation of 8ab and its stereoisomers could be analyzed by chiral 
chromatography. 10 mL of 5 M NaOH was added to the residue, and the reaction was 
heated to 80 °C overnight. After that, the reaction was cooled down and washed with 2 x 
50 mL EtOAc. The pH was then adjusted to 1, and the reaction was extracted with 3 x 50 
mL EtOAc. The extract was dried over Na2SO4. The solvent was passed through a plug 
of CuSO4-impregrated silica gel and co-evaporated with toluene under reduced pressure 










HRESIMS of 8ab m/z 300.1245 [M+Na]+ (300.124551 calculated for C12H23NO4SNa). 
Stereoisomer distribution determined through complementary chiral chromatographies 
(see p. 26): >96% 8ab 
 
1H NMR (400 MHz, chloroform-d) δ 4.32 (m, 1H), 3.45 (m, 1H), 3.39 (s, 3H), 2.55 (m, 
2H), 1.65 (m, 4H), 0.91 (t, J = 7.5 Hz, 3H). 
13C NMR of 9ab (101 MHz, chloroform-d) δ 175.71, 79.92, 65.37, 56.78, 41.31, 38.27, 
25.33, 9.34. 


















Using Precipitate (100 mg precipitate good for 100 mg starting material) 
Synthesis of 8ba & 9ba 
 
6b (20 mg, 0.092 mmol) was added to a solution containing 91 µL NAC (around 10 eq.), 
1.82 mL water, and 2.2 mL of 1 M HEPES (pH 8.5). The thiol-thioester exchange was 
performed over 2 h at 22 °C, and then the pH was adjusted to 7.7 with concentrated HCl. 
291 µL of 5 M NaCl, 2.2 mL of 2.0 M d-glucose, 58 µL of 0.15 M NADP+, 110 µL of 
GDH (15 mg/mL), and 20 mg MycKR6 precipitate were then consecutively added to the 
reaction. The reaction was kept stirring at 22 °C overnight or until it was done monitored 
by LC/MS. Intermediate 8ba could be characterized by HPLC if directly extracted by 
EtOAc (see HPLC before). Heat was applied by microwave, and the aggregated enzyme 
was separated by centrifugation. After that, the reaction was extracted by 450 mL EtOAc. 
The extract was dried over Na2SO4, and the solvent was removed by reduced pressure. 
Formation of 8ba and its stereoisomers could be analyzed by chiral chromatography. 10 
mL of 5 M NaOH was added to the residue, and the reaction was heated to 80 °C 
overnight. After that, the reaction was cooled down and washed with 2 x 50 mL EtOAc. 
The pH was then adjusted to 1, and the reaction was extracted with 3 x 50 mL EtOAc. 
The solvent was passed through a plug of CuSO4-impregrated silica gel and co-








HRESIMS of 8ba m/z 300.1228 [M+Na]+ (300.124551 calculated for C12H23NO4SNa). 
Stereoisomer distribution determined through complementary chiral chromatographies 
(see p. 26): >89% 8ba 
 
1H NMR (400 MHz, chloroform-d) δ 4.33 (s, 1H), 3.47 (s, 1H), 3.39 (s, 3H), 2.54 (m, 
2H), 1.65 (m, 4H), 0.91 (t, J = 7.6 Hz, 3H). 
13C NMR of 9ba (101 MHz, chloroform-d) δ 175.21, 79.84, 65.35, 56.78, 41.36, 38.42, 
25.38, 9.32. 


















Synthesis of 8bb & 9bb 
 
6b (106 mg, 0.486 mmol) was added to a solution containing 500 µL NAC (around 10 
eq.), 10 mL water, and 12 mL of 1 M HEPES (pH 8.5). The thiol-thioester exchange was 
performed over 2 h at 22 °C, and then the pH was adjusted to 7.7 with concentrated HCl. 
800 µL of 5 M NaCl, 6 mL of 2.0 M d-glucose, 160 µL of 0.15 M NADP+, 180 µL GDH 
(15 mg/mL), and 1.0 g of TylKR2 precipitate were then consecutively added to the 
reaction. The reaction was kept stirring at 22 °C overnight or until it was done monitored 
by LC/MS. Heat was applied by microwave, and the aggregated enzyme was separated 
by centrifugation. After that, the reaction was extracted by 450 mL EtOAc. The extract 
was dried over Na2SO4, and the solvent was removed by reduced pressure. Formation of 
8bb and its stereoisomers could be analyzed by chiral chromatography. 10 mL of 5 M 
NaOH solution was added to the residue, and the reaction was heated to 80 °C overnight. 
After that, the reaction was cooled down and washed with 2 x 50 mL EtOAc. The pH was 
then adjusted to 1, and the reaction was extracted with 3 x 50 mL EtOAc. The extract was 
dried over Na2SO4. The solvent was passed through a plug of CuSO4-impregrated silica 
gel and co-evaporated with toluene under reduced pressure to give crude 9bb (22 mg, 









HRESIMS of 8bb m/z 300.1242 [M+Na]+ (300.124551 calculated for C12H23NO4SNa). 
Stereoisomer distribution determined through complementary chiral chromatographies 
(see p. 26): >96% 8bb 
 
1H NMR (400 MHz, chloroform-d) δ 4.24 (m, 1H), 3.48 (m, 1H), 3.38 (s, 3H), 2.55 (m, 
2H), 1.65 (m, 4H), 0.88 (t, J = 7.5 Hz, 3H). 
13C NMR of 9bb (101 MHz, chloroform-d) δ 175.01, 82.52, 68.25, 55.97, 41.48, 38.95, 
25.02, 8.38. 




For the final reaction, the purity of final compounds often depends on the reaction 
conditions. Generally speaking, purer enzyme, less reaction time and lower ambient 
temperature will minimize the byproduct. The byproducts have some peaks similar to 
those of final products on NMR, but they are not the isomers of the final products. That’s 
why for chiral analysis, LC/MS is preferred. If removal of byproducts is desired, silica 









Synthesis of Chemical Standard by catalytic reduction 
High-Pressure Hydrogenation using technology from Parr® Series 4760 Pressure Vessel 
 
 
12 is commercially available  
13a 13b were synthesized according to the following reference with almost full 
conversion37. 
Synthesis of 4a 4b from 13a 13b adopted same procedure as from 3a 3b to 4a 4b. 


























Synthesis of 14a 
800 mg 6a (366 mmol) was dissolved in 40 ml anhydrous methanol, 2.0 g sodium 
methoxide (3700 mmol) was then added portion by portion into the system. The solution 
should have turned into yellowish color. After that, the reaction was monitored by TLC 
(usually 6-9 hours). Methanol was removed when the reaction was done and the residue 
was turned to neutral pH by hydrochloric acid. The aqueous solution was extracted by 
EtOAc 50 ml thrice and dried over Na2SO4. The organic solvent was then removed and 
purification of the residue via column chromatography gave 14a (186 mg, 27 %) as a 
yellowish liquid. Column condition: 3x13 cm. Eluant: 50:1 hexane: EtOAc, 40:1 hexane: 
EtOAc, 30:1 hexane: EtOAc, 10:1 hexane: EtOAc and then 1:1 hexane: EtOAc until all 
product coming out.  
 
1H NMR of 14a (500 MHz, Chloroform-d) δ 3.74 (s, 3H), 3.62 (m, 1H), 3.51 (s, 2H), 
3.32 (s, 3H), 2.74 (dd, J = 14.1, 7.8 Hz, 1H), 2.58 (dd, J = 15.9, 4.5 Hz, 1H), 1.56 (m, 
2H), 0.90 (t, J = 7.4 Hz, 3H). 
13C NMR of 14a (126 MHz, Chloroform-d) δ 201.86, 167.58, 78.18, 56.95, 52.31, 50.02, 
47.06, 26.14, 9.09. 















Synthesis of 14b 
292 mg 6b (134 mmol) was dissolved in 20 ml anhydrous methanol, 756 mg sodium 
methoxide (1400 mmol) was then added portion by portion into the system. The solution 
should have turned into yellowish color. After that, the reaction was monitored by TLC 
(usually 6-9 hours). Methanol was removed when the reaction was done and the residue 
was turned to neutral pH by hydrochloric acid. The aqueous solution was extracted by 
EtOAc 50 ml thrice and dried over Na2SO4. The organic solvent was then removed and 
purification of the residue via column chromatography gave 14b (41 mg, 16 %) as a 
yellowish liquid. Column condition: 1x10 cm. Eluant: 50:1 hexane: EtOAc, 40:1 hexane: 
EtOAc, 30:1 hexane: EtOAc, and then 1:1 hexane: EtOAc until all product coming out.  
 
1H NMR of 14b (500 MHz, Chloroform-d) δ 3.67 (s, 3H), 3.55 (m, 1H), 3.44 (s, 2H), 
3.25 (s, 3H), 2.67 (dd, J = 15.0, 7.8 Hz, 1H), 2.52 (dd, J = 16.1, 4.3 Hz, 2H), 1.50 (m, 
2H), 0.85 (t, J = 7.4 Hz, 3H). 
13C NMR of 14b (126 MHz, Chloroform-d) δ 201.69, 167.41, 77.97, 56.72, 52.08, 49.79, 
46.86, 25.96, 8.90. 














Synthesis of 9aa  
95 mg 14a, 6 mg [Ir-(S)-DTB-SpiroSAP] and 6 mg t-BuOK were dissolved in 2 ml 
anhydrous MeOH. The reaction was quickly relocated in the hydrogenation vessel and 
pressurized to 100 atm. After 2 days, monitored by NMR, the reaction was depressurized 
and the solvent was removed. 5 ml 5M NaOH solution was added to the residue and kept 
at 60 oC overnight. After that, the aqueous solution was washed with 10 ml EtOAc thrice 
and turned pH to 0. The aqueous solution was extracted by EtOAc 50 ml thrice and dried 
over Na2SO4. The organic layer was filtered through a CuSO4 incorporated silica gel 
column. After that, the filtrate was co-evaporated with toluene to give 9aa as a sticky 
yellow liquid without further separation. (70 mg, 77% yield) 
 
1H NMR of 9aa (500 MHz, Chloroform-d) δ 4.24 (s, 1H), 3.44 (m, 1H), 3.34 (s, 3H), 
2.52 (d, J = 6.4 Hz, 2H), 1.63 (m, 4H), 0.86 (t, J = 7.5 Hz, 3H). 



























Synthesis of 9ab 
91 mg 14a, 6 mg [Ir-(R)-DTB-SpiroSAP] and 6 mg t-BuOK were dissolved in 2 ml 
anhydrous MeOH. The reaction was quickly relocated in the hydrogenation vessel and 
pressurized to 100 atm. After 2 days, monitored by NMR, the reaction was depressurized 
and the solvent was removed. 5 ml 5M NaOH solution was added to the residue and kept 
at 60 oC overnight. After that, the aqueous solution was washed with 10 ml EtOAc thrice 
and turned pH to 0. The aqueous solution was extracted by EtOAc 50 ml thrice and dried 
over Na2SO4. The organic layer was filtered through a CuSO4 incorporated silica gel 
column. After that, the filtrate was co-evaporated with toluene to give 9ab as a sticky 
yellow liquid without further separation. (83 mg, 97% yield) 
 
1H NMR of 9ab (500 MHz, Chloroform-d) δ 4.30 (m, 1H), 3.44 (m, 1H), 3.36 (s, 3H), 
2.51 (d, J = 6.0 Hz, 2H), 1.61 (m, 4H), 0.88 (td, J = 7.5 Hz, 3H). 













Synthesis of 9ba  
41 mg 14b, 2 mg [Ir-(S)-DTB-SpiroSAP] and 2 mg t-BuOK were dissolved in 1 ml 
anhydrous MeOH. The reaction was quickly relocated in the hydrogenation vessel and 
pressurized to 100 atm. After 2 days, monitored by NMR, the reaction was depressurized 
and the solvent was removed. 5 ml 5M NaOH solution was added to the residue and kept 
at 60 oC overnight. After that, the aqueous solution was washed with 5 ml EtOAc thrice 
and turned pH to 0. The aqueous solution was extracted by EtOAc 50 ml thrice and dried 
over Na2SO4. The organic layer was filtered through a CuSO4 incorporated silica gel 
column. After that, the filtrate was co-evaporated with toluene to give 9ba as a sticky 
yellow liquid without further separation. (32 mg, 83% yield) 
 
1H NMR of 9ba (500 MHz, Chloroform-d) δ 4.32 (m,1H), 3.46 (m, 1H), 3.37 (s, 3H), 
2.53 (d, J = 6.1 Hz, 2H), 1.62 (m, 4H), 0.89 (t, J = 7.5 Hz, 3H). 













Synthesis of 9bb 
57 mg 14b, 3 mg [Ir-(R)-DTB-SpiroSAP] and 3 mg t-BuOK were dissolved in 2 ml 
anhydrous MeOH. The reaction was quickly relocated in the hydrogenation vessel and 
pressurized to 100 atm. After 2 days, monitored by NMR, the reaction was depressurized 
and the solvent was removed. 5 ml 5M NaOH solution was added to the residue and kept 
at 60 oC overnight. After that, the aqueous solution was washed with 5 ml EtOAc thrice 
and turned pH to 0. The aqueous solution was extracted by EtOAc 50 ml thrice and dried 
over Na2SO4. The organic layer was filtered through a CuSO4 incorporated silica gel 
column. After that, the filtrate was co-evaporated with toluene to give 9bb as a sticky 
yellow liquid without further separation. (46 mg, 86% yield) 
 
1H NMR of 9bb (500 MHz, Chloroform-d) δ 4.25 (m, 1H), 3.44 (m, 1H), 3.34 (s, 3H), 
2.52 (d, J = 5.2 Hz, 2H), 1.62 (m, 4H), 0.86 (t, J = 7.5 Hz, 3H). 













Synthesis of 8aa, 8ab, 8ba, 8bb for LC/MS purpose adapted from following reference6 
 
70 mg 9aa was dissolved in 3 ml anhydrous THF. After that, 24 mg DMAP, 176 mg 
EDC-HCl, 250 mg NAC were added to the system. The slurry was kept stirring overnight 
and then quenched by 1 M HCl solution. The aqueous layer was extracted by EtOAc, and 
dried over Na2SO4. The organic solvent was passed through a CuSO4-packed silica gel 
and removed under reduced pressure. The residue was subjected to LC-MS and HPLC-
UV analysis.  
 
83 mg 9ab was dissolved in 3 ml anhydrous THF. After that, 28 mg DMAP, 207 mg 
EDC-HCl, 280 mg NAC were added to the system. The slurry was kept stirring overnight 
and then quenched by 1 M HCl solution. The aqueous layer was extracted by EtOAc, and 
dried over Na2SO4. The organic solvent was passed through a CuSO4-packed silica gel 
and removed under reduced pressure. The residue was subjected to LC-MS and HPLC-
UV analysis.  
 
32 mg 9ba was dissolved in 3 ml anhydrous THF. After that, 11 mg DMAP, 80 mg EDC-
HCl, 110 mg NAC were added to the system. The slurry was kept stirring overnight and 
then quenched by 1 M HCl solution. The aqueous layer was extracted by EtOAc, and 
dried over Na2SO4. The organic solvent was passed through a CuSO4-packed silica gel 
and removed under reduced pressure. The residue was subjected to LC-MS and HPLC-




46 mg 9bb was dissolved in 3 ml anhydrous THF. After that, 16 mg DMAP, 115 mg 
EDC-HCl, 160 mg NAC were added to the system. The slurry was kept stirring overnight 
and then quenched by 1 M HCl solution. The aqueous layer was extracted by EtOAc, and 
dried over Na2SO4. The organic solvent was passed through a CuSO4-packed silica gel 
and removed under reduced pressure. The residue was subjected to LC-MS and HPLC-
UV analysis.  
 
SUMMARY 
In short, this work was proved as an initial achievement of general polyketide synthesis, 
though much of the work still remains to be optimized. The chemoenzymatic synthesis of 
two-stereocenter triketide building blocks was finished with overall yields of 2.0% of 9aa, 
1.3% of 9ab, 1.7% of 9ba, and 0.9% of 9bb. Synthesis of the triketide products could be 
optimized in yield and stereochemistry, and also protecting group could be modified so 
that it would become easier for removal in the end. As many KRs are capable to establish 
two stereocenters during the reduction of α-substituted, β-ketoacyl substrates20, the 
synthetic routine might be adapted to build libraries of three- or even four-stereocenter 
triketides, via methylmalonyl ethanethiol thioester in C-acylation reactions, for example. 
Further, other PKS enzymes like dehydratases and enoylreductases could be employed to 
modify the functionality of synthesized fragments. With some optimizations, another round 
of C-acylation and subsequent reduction would have chance to produce tetraketides at 
milligram levels. The above described stereoselective synthesis is ecofriendly, heavy-
metal-free, chiral-auxiliary-free, and affordable. If it could be utilized in stereocomplex 
fragments construction, it would be an opportune to synthetic methodology and new 
medicine development in the near future. 
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Chapter 3:  Seven-Enzymes Cascade Reaction Making Diketide431 
INTRODUCTION 
Cascade reaction was always attractive because it allowed our lab to synthesize 
polyketides in one pot. Co-enzyme A was also an important biochemical source in our lab 
that it is a crucial precursor for many bioactive derivatives.  
In previous works44 (R)-3-hydroxybutyrate or enantiomer (S)-3-hydroxybutyrate 
had been generated involving enzymes from the polyhydroxyalkanoate pathway. In 
general, 2 molecules of acetyl-CoA were condensed by thiolase first to give acetoacetyl-
CoA, which was then reduced by reductases to give different enantiomers. After that 
thioesterase would hydrolyze 3-hydroxybutyryl-CoA to provide corresponding 3-
hydroxybutyrate. Different enzymes were tested in these works. For thiolases, thet were 
BktB, Thl, and PhaA; for reductases they were Hbd and PhB; for thioesterases they were 
Ptb-Buk and TesB. Similarly, the reduction system was regenerated by GDH-NADPH 
system also utilized by our lab to produce other diketide building blocks25. 
Inspired by these works, we had various attempts to establish a mature methodology 
to achieve this goal: to utilize Co-A as an intermediate to make diketide in multi-enzyme 
cascade. (3R)-3-hydroxybutyryl-CoA was the first compound imagined in this project.  
RESULTS AND DISCUSSIONS 
Synthesis Design 
The starting material was chosen as commercially available compound in-bulk 
acetic acid. Acetic acid could be grafted onto CoA, to form acetyl CoA using acetyl-CoA 
                                                
1 Parts of this chapter previously published as Luis E. Valencia,a Zhicheng Zhang, Alexis J. Cepeda and Adrian T. Keatinge-Clay, 
“Seven-enzyme in vitro cascade to (3R)-3-hydroxybutyryl-CoA,” Org. Biomol. Chem., 2019, 17, 1375. See statement at end of 
chapter. 
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synthetase (ligase). The reason using CoA as the handle was because shorter handles like 
NAC didn’t work on the enzyme. Longer handles, like pantetheine, were possibly better 
than NAC because the reduction on acetoacetyl-pantetheine could be detected on LC/MS. 
Thus, as the natural substrate CoA no doubt was the best candidate. Acetyl-CoA was then 
condensed by thiolase, like BktB, to generate acetoacetyl-CoA which was similar to 
Claisen condensation. However, the BktB reaction equilibrium was only 1.1 × 10−5, totally 
disfavored in this reaction. In order to drive the reaction forward, other reactions should be 
coupled to drive equilibrium to the right side and render the reaction exergonic.45 Thus, the 
acetoaetyl-CoA should be reduced by reductases as soon as possible to avoid accumulation 
in the system, which would be realized by GDH/NADPH regeneration system25. The 3-
hydroxybutyryl-CoA was then subjected to thiol-thiolester exchange to form 3-
hydroxybutyryl-NAC again in order to facilitate characterizations on chiral UV-HPLC, 
because 3-hydroxybutyryl-CoA was difficult to separate on normal-phase chiral UV-
HPLC due to its strong hydrophilicity (Figure 3.1).  
 
Figure 3.1. Proposed Synthesis Schedule for 3-hydroxybutyryl-NAC. 
Synthesis  
CoA 20 would first be made in situ by cascade reaction involving enzymes CoaA, 
CoaD and CoaE using pantetheine (reduced from pantethine 16), DTT and ATP.46 After 
that, CoA 20 was coupled with acetate to provide acetyl-CoA 21 by ACS. Subsequently 
























buffer and monitored by LCMS until the reaction was done, giving desired product (3R)-
3-hydroxybutyryl-CoA 23. (3R)-3-hydroxybutyryl-CoA 23 could be subjected to thiol-
thiolester exchange to give (3R)-3-hydroxybutyryl-NAC 24 for chiral HPLC analysis 
(Figure 3.2).  
 
 

















































































Figure 3.2B. Synthesis Schedule from CoA 20 to Final Product 23 and 24. 
 
Characterization 
(3R)-3-hydroxybutyryl-CoA was strongly soluble in water thus it was sensitive to 
LCMS detection showing sharp [M-H]- and [M-2H]2- peaks on the graph. This was an easy 
method to demonstrate the existence of target species in order to monitor progress of the 
cascade reaction.  Interestingly, other minor species, such as sodium adduct, could also be 
























































































Figure 3.3. LC/MS Analysis of 23. 
To determine stereochemistry, (3R)-3-hydroxybutyryl-CoA 23 was then undergone 
thiol-thiolester exchange yielding (R)-3-hydroxybutyryl-SNAC 24 for chiral HPLC 
separation. Surprisingly but expected, the HPLC gave perfect result in comparison of 
synthesized chemical standard. It matched the retention time of authentic (R)-3-
hydroxybutyryl-SNAC 24 and no obvious peak of (S)-3-hydroxybutyryl-SNAC 24 was 
detected, which meant the cascade reaction yielded high stereoisomer. Also, in order to 
prove the result, authentic chemical standards (S)-3-hydroxybutyryl-SNAC and (R)-3-
hydroxybutyryl-SNAC were both made synthetically. After comparison on HPLC it turned 
out all the data were congruent. However, this method was failed to characterize product 
by 1H NMR due to impurities in the product. The major byproduct was characterized as 
NAC dimer, which cannot be removed by regular silica chromatography because the 
polarity of NAC dimer resembles that of (S)-3-hydroxybutyryl-SNAC 24 (Figure 3.4). 
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Figure 3.4. UV-HPLC Analysis of 24, showing retention at 29.3 min, NAC dimer is on 
the right side. 
Thus, inspired by peak-suppressing NMR technology, (3R)-3-hydroxybutyryl-CoA 
23 was diluted without thiol-thiolester exchange and passed through Q-Sepharose ion 
exchange column. The column was then washed and eluted with 100mM HCl. The eluent 
containing (3R)-3-hydroxybutyryl-CoA was tested by H NMR and gave clear structure of 
(3R)-3-hydroxybutyryl-CoA 23 (See SI). In addition, P NMR was also taken to double-
prove the result, that the 3 phosphorus peaks indicated the existence of 3 phosphoric 


































See publication in the appendix. 
SUMMARY 
In short, a successful attempt to generate chiral diketide building block (3R)-3-
hydroxybutyryl-CoA was achieved via seven-enzyme reaction in one-pot. The reaction not 
only generated diketide but also valuable intermediate CoA derivatives as well without any 
traditional metal catalysts and high pressure.47 Green chemistry, heavy metal free, high 
efficacy and convenient experimental procedure all render advantages for this cascade 
reaction. More optimization could be done at this point, such as immobilization of enzyme 
in order to reuse the material. Future study are also scheduled to explore more complex 
compounds48 or more facile compounds49 based this methodology. 
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Chapter 4:  Mechanism Study of Pyran Synthase Domain in trans-AT 
Assembly Line502 
INTRODUCTION 
Trans-acyltransferase (trans-ATs) PKSs are a recently discovered PKS type which 
characterize those AT modules not embedded in the whole assembly line on the 
polypeptides. Traditional cis-ATs, however, are located within the assembly line. 
Functional modules in cis-AT PKSs are well studied whereas those, such as double bond 
isomerization, pyran formation, O-methylation, in trans-AT are not.51 
Pyran synthases (PSs) catalyze the cyclization with 5/6-membered ring to form 
ethers in the polyketides made by trans-AT PKSs. They have similarities to dehydratases 
(DHs) but different by an Hx4P motif instead of Hx8P motif found in DH. PSs are widely 
discovered in different trans-AT PKS assembly lines like bryostatin (Bry), diaphorin (Dip), 
luminaolide (Lum), misakinolide (Mis), oocydin (Ooc), pederin (Ped), phormidolide 
(Phm), psymberin (Psy), sorangicin (Sor), spliceostatin (Fr9), thailanstatin (Tst), and 
tolytoxin (Tto). The thailanstatin and sorangicin assembly lines have two and three PSs. 
Except oocydin and phormidolide PSs, which generate 5-membered tetrahydrofuran 
fragment through an ε-hydroxyl group generated from monooxygenase in their 
biosynthetic routines, PSs usually catalyze 1,4-conjugate addition generating six-
membered dihydropyran/tetrahyropyran rings through a ζ-hydroxyl group to Cβ.52  
However, the mechanism of PS is not currently well studied. The trans-AT 
pathways suggested that β-carbon on a trans-α/β-unsaturated double bond was attacked by 
hydroxyl group via oxa-Michael addition.51 For nucleophile, some PSs utilize a D-
                                                
2 Parts of this chapter previously published as Drew T. Wagner, Zhicheng Zhang, Roy A. Meoded, Alexis J. Cepeda, Jörn Piel, and 
Adrian T. Keatinge-Clay, “Structural and Functional Studies of a Pyran Synthase Domain from a trans-Acyltransferase Assembly 
Line,” ACS Chem. Biol., 2018, 13, 4, 975. See statement at end of chapter. 
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hydroxyl group as the nucleophile, whereas others utilize an L-hydroxyl group as the 
nucleophile. For double bond addition, Some PSs catalyze oxa-Michael addition to the re 
face, while others catalyze oxa-Michael addition to the si face. Previous studies from the 
misakinolide and pederin assembly lines (MisPS16 and PedPS9) showed cyclization 
activity on the natural substrate analogue, ζ-hydroxyacyl N-acetylcysteamine (NAC) 
thioester substrates preferred more anti products than syn products. The study of PedPS9 
PS showed that the L-ζ-hydroxy substrate was slightly favored over the D-ζ-hydroxy 
substrate, when in both cases the β-carbon atom on the double bond was attacked at its si 
face (Figure 4.1.).53  
Different Patterns of PS/DH Cyclization with Different Stereochemistry	
 
Figure 4.1. Different Patterns of PS/DH Cyclization with Different Stereochemistry.50 
Herein, a pyran synthase SorPS9 from the Sorangium cellulosum trans-AT 
assembly line, which produced sorangicin antibioticsm,54 was reported by our lab with 1.55 
Å resolution structure. Different synthetic chemical analogues, the trans-α/β-unsaturated ζ-
hydroxyacyl NAC thioester substrates, were tested on wild type and mutated SorPS9s. The 
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mechanism study confirmed that active site of SorPS9 contains a histidine and an 
asparagine residues equivalent to the catalytic histidine and aspartate of DHs.  
 
RESULTS AND DISCUSSIONS 
Structural Study of PS 
See publication in the appendix.	
Synthesis of Chemical Analogues 
Since the natural substrate was complex, the synthesis was simplified to resemble 
natural substrate with NAC-mimics 31 and 37. For the scenario of non-substituted pyran, 
the synthesis started with commercially available compound 26. Ester 26 was carefully 
reduced to colorless aldehyde 27 by DIBAL-H DCM solution at low temperature under 
argon with moderate yield 40.5 %.55 Aldehyde 27 was directly used for the next step 
without separation because aldehyde 27 was perishable to oxygen. Using Doebner-
Knoevenagel condensation and decarboxylation,56 Aldehyde 27 was easily transformed 
into both starting material and product for PS enzymatic reaction acyclic acid 28 and 
cyclized acid 29 via 2 consecutive steps with the ratio nearly 1:1 in one pot. Fore sure 
although oil bath was originally intended for decarboxylation, there was cyclized acid 29 
observed. This implied even without the help of PS, acyclic acid 28 would undergo 
cyclization to form more thermodynamically stable compound acid 29 when temperature 
was raised. The transformation was accelerated at room temperature by PS. After that, by 
simple EDH-HCl coupling with NAC handle, natural substrate analogues 30 and 31 were 
obtained with 44.4 % and 4.7 % yields respectively as yellowish sticky oils. The low 
coupling yield of acyclic acid 29 was attributed to the active hydroxyl proton on the acid. 
For the scenario of methyl-substituted pyran, the reaction protocol was the same with no 
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huge difference. The synthesis started with commercially available compound 32. Ester 32 
was carefully reduced to colorless aldehyde 33 with all possible stereoisomers with low 
yield 21.4 %55 and then aldehyde 33 was directly for use as well. Using the same Doebner-
Knoevenagel condensation and decarboxylation,56 Aldehyde 33 was transformed into both 
starting material and product for PS enzymatic reaction racemic acyclic acid 34 and 
cyclized acid 35 with 27.5 % and 15.0 % yields respectively. The yield of compound 35 
was lower probably due to increased steric hindrance on methyl group. Also synthesized 
cyclized acid 35 was almost in syn configuration according to a previous report,57 which 
was opposite to enzymatic pyran configuration. After that, by simple EDH-HCl coupling 
with NAC handle, natural substrate analogues 36 and 37 were obtained with 51.0 % and 











Figure 4.2. Synthesis of Chemical Analogues 30, 31, 36, 37. 
Conditions: a) DIBAL-H (1.2 eq.), DCM, -78oC, 2h, 40.5% 27/21.4 % 33. b) malonic acid 
(1.0 eq.), pyridine (cat.), piperidine (cat.), r.t., overnight, then oil bath 105 °C for 4 h, 27.2 
% 28/25.7 % 29/27.5 % 34/17.0 % 35. c) EDC-HCl (2.0 eq.), DCM, N-acetylcysteamine 
(NAC) (1.2 mmol), DMAP (cat.), r.t., 4h, 44.4 % 30/4.7 % 31/51.0 % 36/31.0 % 37.	
Enzymatic Reactions 
In order to test the enzyme activity, wild type SorPS9 was incubated with substrate 
mimic 31 overnight at 22 °C. Liquid chromatography/mass spectrometry (LC/MS) analysis 
reflected the disappearance of 31 and new peaks not observed in negative control 
respectively. Consistent with pyran formation, the characteristic UV absorbance of the new 
peak shifted from 265 nm (trans-α/β-unsaturated thioester substrate) to 230 nm. Then 
methyl-substituted 37 was subjected to SorPS9 giving the similar result. LC/MS analysis 
showed the disappearance of 37a and 37b and two roughly equal new peaks with the same 
mass of the substrates. This demonstrated that SorPS9 generated products from both D- 
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and L-ζ-hydroxy substrates. In addition, when SorPS9 was incubated with cyclized pyran 
products (30 and 36), no starting material (31 and 37) was detected. This implied the 
reaction equilibrium heavily favors pyran formation. Also, Other mutated SorPS9, H33A, 
N186H, N186A, and N186D, were generated and incubated with SorPS9 to determine the 
active site of SorPS9. For the H33A mutant,	no discernible activity was detected. This 
indicated the histidine residue was catalytic. For the N186H mutant, activity was 
significantly retained. For the N186A and N186D mutants, the activities were reduced to 





Figure 4.3. Activity Assays of SorPS9 and Point Mutants. LC/MS analysis of incubations 
with 31/37 revealed wild-type SorPS9 generated 30/36, while the H33A mutant was 
inactive. In both cases, the N186H and N186A mutants showed some activity, but no 
activity was observed from the N186D mutant. Traces show extracted ion current at m/z 
268/282 respectively.50 
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Brief Mechanism of PS  
Thus, it turned out H33 and N186 were crucial residues catalyzing the ring 
formation in SorPS9. The proposed mechanism involved the H33, N186 and a molecule of 
water created by A39 in an oxyanion hole. First, the water molecule and N186 form 
hydrogen bond to stabilize the new entered substrate. Second, the ζ-hydroxyl attacked β-
trans-double bond to generate the oxyanion intermediate. After that, H33 functioned as a 
proton acceptor to remove the proton from the pyran oxygen and then transferred it finally 
to enolate oxygen. The cyclized pyran product left the active site. Since σ bond was 
stronger than π bond, the pyran formation was actually irreversible. Regarding the 
stereochemistry, SorPS9 catalyzed addition at Cβ on the re face whereas most PSs 
catalyzed addition on the si face. However, attacking on the si face was possible if the 
thioester adopted s-cis conformation (Figure 4.4). Therefore, the preferred conformation 
of a substrate in the PS active site would tell whether to adopt the s-cis or s-trans geometry 












Figure 4.4. Proposed Mechanism of PS Active Site and Conformation of Oxa-Michael 













In short, the structure and mechanism of SorPS9 from trans-AT assembly lines 
were studied. Different simplified chemical analogues were synthesized to test the enzyme 
activity. Mutagenesis was performed to successfully locate the residues charging the 
substrate cyclization. As the result, the active site of SorPS9 included a histidine residue 
mediating proton transfer, and the asparagine residue helping create the oxyanion hole 
through a water molecule. It turned out SorPS9 is capable to generate chiral pyran ring 
which could be utilized as an efficent biocatalyst. With the development of research, more 
mysteries will be revealed in trans-AT assembly lines so that they could be employed and 
engineered as biocatalyst to provide unusual reactions or even help generate new valuable 
medicines in the future.  
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Chapter 5:  Structural and Mechanism Study of gem-Dimethylating 
Methyltransferase from a trans-AT Assembly Line583 
BRIEF INTRODUCTION  
The methyl substituents in polyketides made by trans-acyltransferase assembly 
lines are usually deprived from S-adenosylmethionine (SAM)-dependent 
methyltransferase (MT) domains. The MT from polyketide disorazol assembly lines 
DisMT3 was revealed with 1.75-Å-resolution crystal structure in this work. Mutagenesis 
on β-ketoacyl chains to an acyl carrier protein handle (ACP) and N-acetylcysteamine 
handle were conducted and tested on the activities. This provided the mechanism of MT 
active site residues. An alanine replacement with a phenylalanine at an obvious 
gatekeeping position (A326F) led in more monomethylation than demethylation (Figure 
5.1). 
                                                
3 Parts of this chapter previously published as Jessica L. Meinke, M. Rachel Mehaff ey, Drew T. Wagner, Ningze Sun, Zhicheng 
Zhang, Jennifer S. Brodbelt, and Adrian T. Keatinge-Clay, “Structural and Functional Studies of a gem-Dimethylating 




Figure 5.1. The Model of DisMT3 and Mutagenesis Study on LC/MS.58 
My work included synthesis of monomethylated and dimethylated analogues	α-
methyl-β-ketopentanoyl-SNAC and α-dimethyl-β-ketopentanoyl-SNAC as chemical 
standards for Wild-type DisMT3 enzyme activity test. The result turned out, wild-type 
DisMT3 did not yield any gem-dimethylated product but did only generate some 
monomethylated product (Figure 5.2). 
 
 
Figure 5.2. Reaction of DisMT3 with Ketopentanoyl-SNAC. The Product Structure of α-
methyl-β-ketopentanoyl-SNAC	and	α-dimethyl-β-ketopentanoyl-SNAC. 
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Also, only the Y170F point mutant provided traceable levels of the 
monomethylated product. This suggested that the interaction between the MT and ACP 
domains might be important to transfer moth methyl groups. The DisMT3 and NAC 
mimics didn’t provide sufficient binding energy to forward the second methylation. In 
addition, the N285A, E314A, and E314Q mutants suffered more activity loss in scenario 
of the SNAC-bound substrate than that in the ACP-bound substrate. Maybe small 
molecules were more dependent on active site residue interaction. This result helped to 
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Chapter 6:  Structural Study of Four-Helix Bundle Docking Domain in 
trans-Acyltransferase Modular Polyketide Synthases594 
BRIEF INTRODUCTION 
In PKS assembly lines, domain-domain connection involves both covalent 
connection and non-covalent connection. In the non-covalent connection situation, docking 
domain plays in important role to interconnect those PKS domains in the correct order. 
Recently, new discovery has been made in trans-acyltransferase polyketide synthases. 
These 25-residue, two helix, pseudosymmetric docking domains are found in the C-termini 
and N-termini of many polypeptides. The motifs connect domains between and with PKS 
modules. A 1.72 Å-resolution structure of the N-terminal portion of the MlnE (macrolactin 
synthase polypeptide) had been revealed as an uncomplexed and preorganized N-terminal 
docking motif (Figure 6.1).  
                                                
4 Parts of this chapter previously published as Jia Zeng, Drew T. Wagner, Zhicheng Zhang, Luisa Moretto, Janci D. Addison, and 
Adrian T. Keatinge-Clay, “Portability and Structure of the Four-Helix Bundle Docking Domains of trans-Acyltransferase Modular 




Figure 6.1. Mln Synthesis Assembly Line and The Four-Helix Docking Motifs between 
KS in MlnD and KR in MlnE.59 
My work included preparing those PKS modules with modified docking domains. 
By targeted domain swapping, different chimera protein complexes with compatible CDD 




Figure 6.2. Polypeptide Association Mediated by DD Motifs. Each stained SDS/PAGE gel 
shows fractions 8−16 from size-exclusion chromatography. (A) Each pair of constructs 
containing cognate DD motifs apparently formed complexes. Each pair of constructs 
containing non-cognate DD motifs did not show complex formation. (B) The removal of 
CDDs resulted in no complex formation, indicating that they are necessary in mediating an 
association with a polypeptide containing a cognate NDD. (C) When CDDs were swapped 
between constructs, they were sufficient to mediate the association with a polypeptide 
containing a cognate NDD. Gels showing complex formation are boxed in red. (D) 
Representative size exclusion chromatograms showing constructs not possessing matching 
docking motifs migrating as if they had been run individually as well as constructs 
possessing matching docking motifs migrating more quickly.59 
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Conclusion and Future Directions 
Polyketide synthases are shining and attracting more and more researchers to delve 
into this area. In Chapter 2, we demonstrated a total synthesis of triketide building blocks 
with the help form ketoreductases. In Chapter 3, we successfully utilize different enzymes 
to synthesize a useful polyketide with great stereochemistry in one-pot. In Chapter 4, we 
synthesize chemical analogues to test the activities of wild type pyran synthase and its 
mutants to determine the active site residues. In Chapter 5, we attempted to assay the 
methylation activity of both natural products and analogues to explore the mechanism of 
methyltransferase. In Chapter 6, we elucidated the structural of a docking motif located in 
a trans-acyltransferase assembly line and conducted docking domain swapping to creat 
new protein complex.  
However, we are not satisfied with our current situation. Our laboratory is looking 
forward to employ more enzymes from PKS assembly line to create more valuable chiral 
compounds potential for pharmaceutical industry. Also, we would be gratefully to update 











































































































































































Chemical Formula: C9H17NO3S 
 
 



























































































































Chemical Formula: C9H17NO3S 
 
 















































































































Chemical Formula: C5H10O3 
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S-(2-acetamidoethyl) (3S,5S)-3-hydroxy-5-methoxyheptanethioate (enzyme) 
Chemical Formula: C12H23NO4S 
 
 












Conclusion on HPLC and LCMS: 90% 8aa   











S-(2-acetamidoethyl) (3R,5S)-3-hydroxy-5-methoxyheptanethioate (enzyme) 
Chemical Formula: C12H23NO4S 
 
 














Conclusion on HPLC and LCMS: 96% 8ab   












S-(2-acetamidoethyl) (3S,5R)-3-hydroxy-5-methoxyheptanethioate (enzyme) 









start time stop time value area species %
Width 26.211 29.085 2.87447 26189.3 ab+ba 94.8
Threshold 26.171 29.006 9111
Width 31.37 33.969 2.59908 610.7838 bb 2.2
Threshold 31.37 34.01 235
Width 35.348 37.829 2.48148 813.9254 aa 3








Conclusion on HPLC and LCMS: 89% 8ba  











S-(2-acetamidoethyl) (3S,5S)-3-hydroxy-5-methoxyheptanethioate (enzyme) 
Chemical Formula: C12H23NO4S 
 
 








start time stop time value area species %
Width 25.733 27.48 1.7463 1901.721 ab+ba 3.1
Threshold 25.763 27.655 1089
Width 30.418 34.143 3.72464 59042.99 bb 96.1
Threshold 30.36 34.23 15852
Width 34.958 36.994 2.03662 496.9353 aa 0.8








Conclusion on HPLC and LCMS: 96% 8bb   












(3S,5S)-3-hydroxy-5-methoxyheptanoic acid (enzyme) 










































































































































































(3R,5S)-3-hydroxy-5-methoxyheptanoic acid (enzyme) 















































































































































































(3S,5R)-3-hydroxy-5-methoxyheptanoic acid (enzyme) 














































































































































(3R,5R)-3-hydroxy-5-methoxyheptanoic acid (enzyme) 



















































































































































































Figure S0-1. Normal phase HPLC-UV and Reverse phase LC/MS analysis of actual 
















Figure S0-2. Normal phase HPLC-UV and Reverse phase LC/MS analysis for internal 















































S-(2-acetamidoethyl) (3S,5S)-3-hydroxy-5-methoxyheptanethioate (chemical) 
Chemical Formula: C12H23NO4S 
 

























S-(2-acetamidoethyl) (3R,5S)-3-hydroxy-5-methoxyheptanethioate (chemical) 
Chemical Formula: C12H23NO4S 
 


























S-(2-acetamidoethyl) (3S,5R)-3-hydroxy-5-methoxyheptanethioate (chemical) 
Chemical Formula: C12H23NO4S 
 

























S-(2-acetamidoethyl) (3R,5R)-3-hydroxy-5-methoxyheptanethioate (chemical) 
Chemical Formula: C12H23NO4S 
 


























 Enzymatic Synthesis 
8aa -15.7 min -14.1 min 
8ab -20.6 min -19.7 min 
8ba -27.7 min -27.3 min 
8bb -17.2 min -17.7 min 
 
















 Enzymatic Synthesis 
8aa 10.4 min 10.8 min 
8ab 0.0 min 0.0 min 
8ba 0.6 min 0.6 min 
8bb 6.0 min 5.6 min 
 
Table S2. HPLC Corrected Retention Time (In comparison to 8ab) 
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